Advanced BioMedical Technologies (Advanced BioMedical Technologies) Cash-to-Debt : 0.64 (As of Jul. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Advanced BioMedical Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Advanced BioMedical Technologies's cash to debt ratio for the quarter that ended in Jul. 2021 was 0.64.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Advanced BioMedical Technologies couldn't pay off its debt using the cash in hand for the quarter that ended in Jul. 2021.

The historical rank and industry rank for Advanced BioMedical Technologies's Cash-to-Debt or its related term are showing as below:

ABMT's Cash-to-Debt is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.875
* Ranked among companies with meaningful Cash-to-Debt only.

Advanced BioMedical Technologies Cash-to-Debt Historical Data

The historical data trend for Advanced BioMedical Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Advanced BioMedical Technologies Cash-to-Debt Chart

Advanced BioMedical Technologies Annual Data

Trend

Oct11

Oct12

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

5.77

Advanced BioMedical Technologies Quarterly Data
	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21
Cash-to-Debt	Get a 7-Day Free Trial															0.31	5.77	0.33	0.43	0.64

Competitive Comparison of Advanced BioMedical Technologies's Cash-to-Debt

For the Medical Devices subindustry, Advanced BioMedical Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced BioMedical Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Cash-to-Debt falls into.

Advanced BioMedical Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Advanced BioMedical Technologies's Cash to Debt Ratio for the fiscal year that ended in Oct. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.202	/	(0.028	+	0.007)
	=	5.77

Advanced BioMedical Technologies's Cash to Debt Ratio for the quarter that ended in Jul. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.007	/	(0.011	+	0)
	=	0.64

Advanced BioMedical Technologies (OTCPK:ABMT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Advanced BioMedical Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Advanced BioMedical Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced BioMedical Technologies (Advanced BioMedical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced BioMedical Technologies Inc (OTCPK:ABMT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Park Avenue, Suite 1700, New York, NY, USA, 10166

Website

https://www.abtbiomedical.com

Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.

Executives

Advanced Biomedical Technologies Inc.	director, officer: CFO	200 PARK AVENUE, SUITE 1700 NEW YORK NY 10166
Lynch John Thomas Jr	other: Advisor	22 MULBERRY STREET SUITE 1B MIDDLETOWN NY 10940
Chi Ming Yu	director, 10 percent owner, officer: PRESIDENT	36 CLAREMONT TERRACE WAYNE NJ 07470
Andriy Protskiv	director, 10 percent owner, officer: President, CEO, CFO	706-15038 101 AVENUE SURREY A1 V3R 0N2

Advanced BioMedical Technologies (Advanced BioMedical Technologies) Headlines

From GuruFocus

Advanced Biomedical Technologies Inc. Launches Sales Campaign

By Marketwired Marketwired • 11-06-2019

Advanced Biomedical Technologies Inc. Announces Chinese CFDA Approval of Polymer Fixation Screws

By Marketwired Marketwired • 04-19-2018